Truist raised the firm's price target on Lantheus to $115 from $98 and keeps a Buy rating on the shares. Pylarify delivered its 3rd consecutive beat at $241M and flat-to-up sequential revenue growth, suggesting further PYL stabilization, the analyst tells investors in a research note.
